Psyon

Psyon Therapeutics is a preclinical-stage biotechnology company focused on developing "on-target" activated biologics to treat solid tumors. The company's proprietary platform utilizes protease-sensitive linkers to keep potent therapies, such as cytokines and antibodies, in an inactive state until they reach the tumor microenvironment. By leveraging the unique enzymatic activity within tumors, Psyon aims to maximize therapeutic efficacy while minimizing systemic toxicity. This approach addresses the narrow therapeutic index often associated with systemic administration of potent immune-modulators. The company is currently advancing a pipeline of conditionally active agents designed to provide safer and more effective cancer treatments.